BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 30

• Drug Development

  CLI Data From Cesca Therapeutics’s Phase I/Phase II And Feasibility Studies To Be Presented At The American Heart Association-Scientific Sessions Conference By Richard Powell, M.D.

  November 9, 2015

   · 

  5 min read
• Drug Development

  ZS Pharma Announces Positive Interim Results From A Long-Term Safety Study Of ZS-9

  November 9, 2015

   · 

  8 min read
• Lone Star Bio

  Xbiotech Announces Positive Results For Its Anti-Ebola Therapeutic Candidates Following Evaluation By USAMRIID

  November 9, 2015

   · 

  5 min read
• Policy

  Collegium Announces FDA Tentative Approval For Xtampza(TM) ER, A Novel Abuse-Deterrent Analgesic For Chronic Pain

  November 9, 2015

   · 

  5 min read
• Pharm Country

  Boehringer Ingelheim Highlights Latest Community And Research Initiatives In Advancing Anticoagulation Care At American Heart Association Scientific Sessions 2015

  November 9, 2015

   · 

  5 min read
• Drug Development

  Immune Pharma Announces FDA Acceptance Of Investigational New Drug (IND) Application In The U.S. For Bertilimumab For The Treatment Of Bullous Pemphigoid

  November 9, 2015

   · 

  6 min read
• Drug Development

  Kite Pharma Initiates Phase II Clinical Study Of KTE-C19 (ZUMA-2) In Patients With Relapsed Or Refractory Mantle Cell Lymphoma (R/R MCL) To Support Registration For A Second Indication

  November 9, 2015

   · 

  3 min read
• Drug Development

  Akebia Therapeutics, Inc. Announces Presentation of Vadadustat Phase II Dialysis Data at American Society of Nephrology Kidney Week 2015 Annual Meeting

  November 9, 2015

   · 

  7 min read
• Drug Development

  Upsher-Smith Laboratories Release: Data Published In Epilepsia Shows USL261 (Intranasal Midazolam) Demonstrated A Promising Pharmacokinetic Profile, Including Increased Relative Bioavailability, When Compared With Injectable Midazolam Administered Intrana

  November 9, 2015

   · 

  5 min read
• Policy

  ScinoPharm Changshu Site Completed US FDA Inspection

  November 9, 2015

   · 

  3 min read